Cargando…

Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use

BACKGROUND: The optimal treatment of early syphilis (primary, secondary and early latent) in HIV-infected patients remains controversial. The Center for Diseases Control STD Treatment Guidelines recommended 1 dose of benzathine penicillin G (BPG) regardless of HIV infection. However, many providers...

Descripción completa

Detalles Bibliográficos
Autores principales: Jinno, Sadao, Anker, Bryan, Kaur, Parveen, Bristow, Claire C, Klausner, Jeffrey D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877955/
https://www.ncbi.nlm.nih.gov/pubmed/24369955
http://dx.doi.org/10.1186/1471-2334-13-605
_version_ 1782297723412676608
author Jinno, Sadao
Anker, Bryan
Kaur, Parveen
Bristow, Claire C
Klausner, Jeffrey D
author_facet Jinno, Sadao
Anker, Bryan
Kaur, Parveen
Bristow, Claire C
Klausner, Jeffrey D
author_sort Jinno, Sadao
collection PubMed
description BACKGROUND: The optimal treatment of early syphilis (primary, secondary and early latent) in HIV-infected patients remains controversial. The Center for Diseases Control STD Treatment Guidelines recommended 1 dose of benzathine penicillin G (BPG) regardless of HIV infection. However, many providers modify the treatment for early syphilis. METHODS: We performed a retrospective chart review of all cases of early syphilis with positive serologic test results in HIV-infected patients from May 2006 to May 2011 in 2 large, urban HIV clinics. Early syphilis includes primary, secondary, and early latent syphilis. Serological failure was defined as a lack of 4-fold decrease in rapid plasma reagent (RPR) titers 9 to 12 months after syphilis treatment. Patients whose RPR titers decreased after treatment and subsequently increased 4-fold at 9 to 12 months were excluded from the analysis of serological response because of possibility as “reinfection”. Baseline characteristics were tested as predictive factors of serological failure using a univariate and multivariate logistic regression model, respectively. RESULTS: Of 560 patients with confirmed cases of early syphilis, 51 (9.0%) experienced serological failure. Multivariate logistic regression modeling demonstrated that the predictive factors associated with serological failure after early syphilis treatment were baseline RPR titer ≤ 1:16 (OR 3.91 [95% CI, 2.04-7.47]), a previous history of syphilis (OR 3.12 [95% CI, 1.55-6.26]), and a CD4 T-cell count below 350 cells/ml (OR 2.41 [95% CI, 1.27-4.56]). Of note, type of syphilis treatment (1 dose versus 3 doses of BPG) did not appear to affect the proportion of serological failure (4% versus 10%, P = 0.29), however the power of this study to detect small differences was limited. CONCLUSIONS: HIV-infected patients with baseline RPR titer ≤1:16, syphilis history, and/or a CD4 T-cell count <350 cells/ml should be closely monitored for serologic failure after early syphilis treatment. This study did not detect a substantial difference between treatment with > 1 dose of BPG and decreased frequency of serological failure, supporting the current recommendation that one dose of BPG is adequate treatment for early syphilis in HIV-infected patients.
format Online
Article
Text
id pubmed-3877955
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38779552014-01-03 Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use Jinno, Sadao Anker, Bryan Kaur, Parveen Bristow, Claire C Klausner, Jeffrey D BMC Infect Dis Research Article BACKGROUND: The optimal treatment of early syphilis (primary, secondary and early latent) in HIV-infected patients remains controversial. The Center for Diseases Control STD Treatment Guidelines recommended 1 dose of benzathine penicillin G (BPG) regardless of HIV infection. However, many providers modify the treatment for early syphilis. METHODS: We performed a retrospective chart review of all cases of early syphilis with positive serologic test results in HIV-infected patients from May 2006 to May 2011 in 2 large, urban HIV clinics. Early syphilis includes primary, secondary, and early latent syphilis. Serological failure was defined as a lack of 4-fold decrease in rapid plasma reagent (RPR) titers 9 to 12 months after syphilis treatment. Patients whose RPR titers decreased after treatment and subsequently increased 4-fold at 9 to 12 months were excluded from the analysis of serological response because of possibility as “reinfection”. Baseline characteristics were tested as predictive factors of serological failure using a univariate and multivariate logistic regression model, respectively. RESULTS: Of 560 patients with confirmed cases of early syphilis, 51 (9.0%) experienced serological failure. Multivariate logistic regression modeling demonstrated that the predictive factors associated with serological failure after early syphilis treatment were baseline RPR titer ≤ 1:16 (OR 3.91 [95% CI, 2.04-7.47]), a previous history of syphilis (OR 3.12 [95% CI, 1.55-6.26]), and a CD4 T-cell count below 350 cells/ml (OR 2.41 [95% CI, 1.27-4.56]). Of note, type of syphilis treatment (1 dose versus 3 doses of BPG) did not appear to affect the proportion of serological failure (4% versus 10%, P = 0.29), however the power of this study to detect small differences was limited. CONCLUSIONS: HIV-infected patients with baseline RPR titer ≤1:16, syphilis history, and/or a CD4 T-cell count <350 cells/ml should be closely monitored for serologic failure after early syphilis treatment. This study did not detect a substantial difference between treatment with > 1 dose of BPG and decreased frequency of serological failure, supporting the current recommendation that one dose of BPG is adequate treatment for early syphilis in HIV-infected patients. BioMed Central 2013-12-26 /pmc/articles/PMC3877955/ /pubmed/24369955 http://dx.doi.org/10.1186/1471-2334-13-605 Text en Copyright © 2013 Jinno et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Jinno, Sadao
Anker, Bryan
Kaur, Parveen
Bristow, Claire C
Klausner, Jeffrey D
Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use
title Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use
title_full Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use
title_fullStr Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use
title_full_unstemmed Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use
title_short Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use
title_sort predictors of serological failure after treatment in hiv-infected patients with early syphilis in the emerging era of universal antiretroviral therapy use
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877955/
https://www.ncbi.nlm.nih.gov/pubmed/24369955
http://dx.doi.org/10.1186/1471-2334-13-605
work_keys_str_mv AT jinnosadao predictorsofserologicalfailureaftertreatmentinhivinfectedpatientswithearlysyphilisintheemergingeraofuniversalantiretroviraltherapyuse
AT ankerbryan predictorsofserologicalfailureaftertreatmentinhivinfectedpatientswithearlysyphilisintheemergingeraofuniversalantiretroviraltherapyuse
AT kaurparveen predictorsofserologicalfailureaftertreatmentinhivinfectedpatientswithearlysyphilisintheemergingeraofuniversalantiretroviraltherapyuse
AT bristowclairec predictorsofserologicalfailureaftertreatmentinhivinfectedpatientswithearlysyphilisintheemergingeraofuniversalantiretroviraltherapyuse
AT klausnerjeffreyd predictorsofserologicalfailureaftertreatmentinhivinfectedpatientswithearlysyphilisintheemergingeraofuniversalantiretroviraltherapyuse